Negotiating Price Negotiation: Why the Democrats Will Struggle to Pressure Part D Prices
This article was originally published in RPM Report
The new Congress wants to make federal price negotiation under Medicare a reality. But it won't be easy. Big Pharma should expect plenty of interference from the Democrats in Part D, but it is hard to see a meaningful impact on prices in the near term.
You may also be interested in...
The 700-page Part D proposed rule does much more than change the "protected" class list. Among many other provisions, it spells out how CMS interprets the infamous "non-interference" clause.
Democratic Sen. Bill Nelson of Florida may have made a tactical error in bringing up an amendment to mandate drug rebates under Medicare Part D during the Senate Finance Committee’s markup of health reform legislation.
The health care reform debate is entering the critical phase. Here are our predictions for where the legislation will end up.